References
- MaisonneuvePLowenfelsABEpidemiology of pancreatic cancer: an updateDig Dis2010284–564565621088417
- SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
- SpanierBWDijkgraafMGBrunoMJEpidemiology, aetiology and outcome of acute and chronic pancreatitis: an updateBest Prac Res Clin Gastroenterol20082214563
- TajimaYKurokiTTsutsumiRIsomotoIUetaniMKanematsuTPancreatic carcinoma coexisting with chronic pancreatitis versus tumor-forming pancreatitis: diagnostic utility of the time-signal intensity curve from dynamic contrast-enhanced MR imagingWorld J Gastroenterol200713685886517352014
- MartinaMCCassinisMCTapperoCGandiniGNon invasive methods in competition for EUS (US, CE-US, CT, MRI and PET/CT): the radiologist point of viewMinerva Med200798434335017921948
- KauhanenSPKomarGSeppänenMPA prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancerAnn Surg2009250695796319687736
- FarmaJMSantillanAAMelisMPET/CT fusion scan enhances CT staging in patients with pancreatic neoplasmsAnn Surg Oncol20081592465247118551347
- ZimnyMFassJBaresRFluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinomaScand J Gastroenterol200035888388810994629
- Dranka-BojarowskaDLekstanAOlakowskiMThe assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitisJ Physiol Pharmacol201566565366326579571
- FriessHLanghansJEbertMDiagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomographyGut19953657717777797130
- EllPJPET/CT in oncology: a major technology for cancerChang Gung Med J200528527428316086542
- DelbekeDPinsonCWPancreatic tumors: role of imaging in the diagnosis, staging and treatmentJ Hepatobiliary Pancreat Surg200411141015747028
- ReskeSNGrillenbererKGGlattingGOverexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinomaJ Nucl Med1997389134413489293784
- BallehaninnaUKChamberlainRSThe clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisalJ Gastrointest Oncol20123210511922811878
- OkusakaTYamadaTMaekawaMSerum tumor markers for pancreatic cancer: the dawn of new era?J Pancreas200674332336
- SinghSTangSJSreenarasimhaiahJLaraLFSiddiquiAThe clinical utility and limitations of serum carbohydrate antigen (CA 19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinomaDig Dis Sci20115682491249621516323